sorry I don’t understand your point. You’re saying it’s not significant. This company has appointed the ex chief statistician of FDA Neurology. So? Nothing to do with Acadia’s approval.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-79
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.14 |
Change
-0.130(0.85%) |
Mkt cap ! $1.935B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.47 | $14.93 | $7.335M | 485.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7079 | $15.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.17 | 3189 | 3 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |